Serum Cav-1 has also been shown to be elevated in men with prostate cancer compared to men with benign prostatic hyperplasia62, to be associated with localized tumor burden1, and as a possible marker to predict prostate cancer recurrence following radical prostatectomy3. This evidence concerns the gene CAV1 and prostate carcinoma.